Sangamo Therapeutics, Inc. (SGMO) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
Portfolio Pulse from
Levi & Korsinsky is investigating Sangamo Therapeutics, Inc. for potential federal securities law violations. This follows Pfizer's decision to return development and commercialization rights for a hemophilia A gene therapy candidate, impacting Sangamo's prospects.
January 13, 2025 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sangamo Therapeutics is under investigation for potential securities law violations after Pfizer returned rights for a key gene therapy candidate, which could negatively impact its stock.
The investigation by Levi & Korsinsky into potential securities law violations is significant, especially following Pfizer's decision to return rights for a key therapy. This could lead to investor uncertainty and a negative impact on SGMO's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100